Top, NEPC biology is estimated to drive approximately 25% of the lethal prostate cancers indicated by the blue zone. Top, NEPC biology is estimated to.

Slides:

Advertisements

Similar presentations

Cancer – a disease of many mutations

Advertisements

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

Modulation of KRASG12C activity alters ARS-853 target engagement and supports novel therapeutic strategies for targeting KRAS. A, schematic for altering.

HER2/HER3 heterodimers in prostate cancer

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

therapy and to block androgen action

PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.

Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.

Figure 1 Critical signalling pathways involved in PDAC pathogenesis

Coordinate Transcriptional Regulation by ERG and Androgen Receptor in Fusion- Positive Prostate Cancers Yu Chen, Charles L. Sawyers Cancer Cell Volume.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

ASSIGNMENT 10 Use the UP and DOWN tags as provided and query the LINCS. These are the KRAS-DEP (UP) and KRAS-IND (DOWN) gene signatures from Singh et al.

CHK1 downregulation upon ERG overexpression.

Types of biomarkers/biosignatures to be used for cardiovascular disease. Types of biomarkers/biosignatures to be used for cardiovascular disease. There.

Altered pathways in prostate cancer.

Alterations related to androgen signaling.

Genetic landscape of salivary duct carcinoma.

Activated membrane signaling promotes survival in response to radiation. Activated membrane signaling promotes survival in response to radiation. Radiation.

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

Nat. Rev. Urol. doi: /nrurol

Oncogenic ALK signaling.

Nat. Rev. Urol. doi: /nrurol

Proposed spiral model for prostate cancer progression.

USP2a-dependent miRs deregulation modulates MYC expression.

Temporal order of mutational processes during cancer evolution.

Inhibition of lung cancer cell proliferation and viability by CYT387.

Schematic representation of the therapeutic strategies that can be applied to target ARF876L. Schematic representation of the therapeutic strategies that.

A, Top inhibitors of Ba/F3 transformed with CD74–ROS1, color coded by clinical development status: FDA-approved (green), phase III (yellow), phase II (blue),

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Integrated mRNA and microRNA expression and DNA methylation clusters.

Inhibitory effect of different doses of IP6 on prostate tumor progression in TRAMP mice. Inhibitory effect of different doses of IP6 on prostate tumor.

VEGF expression in neoplastic and normal prostate tissue.

Active AR signaling in enzalutamide-resistant xenograft tumors.

Parity explains the age-associated increase in ANA prevalence in women ages 12 to 59 years, but not in those ages 60+. Parity explains the age-associated.

Temporal and spatial dissection of mutation spectra in esophageal adenocarcinoma samples. Temporal and spatial dissection of mutation spectra in esophageal.

Per1 inhibits growth and induces apoptosis in prostate cancer cell lines. Per1 inhibits growth and induces apoptosis in prostate cancer cell lines. LNCaP,

Activation of membrane-associated Akt is associated with loss of apoptosis in TgAPT121;Pten+/− prostates. Activation of membrane-associated Akt is associated.

A, Stacked Venn plots of the significantly associated (FDR < 25%) KEGG pathways for 3 imaging subtypes with GSEA. B, Pathway activity scores for 3 imaging.

Changes in signal transduction pathway induced by gefitinib.

High-throughput drug screen (HTDS) reveals ARS1620 and PI3K pathway inhibitors synergies and a heterogeneous pattern of RTK synergies. High-throughput.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Differences in the values of HbA1c variables between the retinopathy-positive and retinopathy-negative groups at year 20. Differences in the values of.

EMT alters activation of AKT and serum-independent proliferation.

Change in FES uptake in the tumor during fulvestrant treatment.

Possible outcomes of therapeutic treatments using the spiral model.

Metastatic signals respond to castration.

The critical roles of miR-23a and miR-27a in colorectal cancer progression. miR-23a primarily increases cell motility through downregulation of its target.

Histology (H&E; original magnification, ×100 for B-2P/C-12P/C-64P and ×40 for C-10P; top) of small-sized lung adenocarcinomas and immunohistochemical staining.

Myc succeeds Akt activation and is required for growth of metastatic prostate cancer. Myc succeeds Akt activation and is required for growth of metastatic.

Global mutational landscape of the 170 lung adenocarcinoma patients (discovery cohort). Global mutational landscape of the 170 lung adenocarcinoma patients.

A, cell number was assessed 96 hours after exposure to indicated treatment in indicated cell models. A, cell number was assessed 96 hours after exposure.

DHT-dependent phase of prostate cancer.

Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Tracking resistance to TRKA inhibition in ctDNA of a patient with.

Survival, subsequent therapies, and response.

Effects of W. chinensis extract on androgen activity and growth of prostate cancer cells. Effects of W. chinensis extract on androgen activity and growth.

High nuclear β-catenin levels confer resistance to AKT inhibition and coordinates with increased nuclear FOXO3a to promote metastasis in colon cancer.

Representative images for different populations of detected cells in prostate cancer patients and five rounds of FISH in a CTC. A, Immunofluorescence image.

HER2 and PI3K-targeted therapies result in FOXO3a-mediated feedback upregulation of HER3 and IGF1R and provide an escape from PI3K pathway inhibition.

Compartmentalized cellular functions of KDM4A.

Core melanoma escape pathways during disease progression on BRAF inhibitor therapy. Core melanoma escape pathways during disease progression on BRAF inhibitor.

EPHA2 inhibitors inhibit phosphorylation of AKT and ERK, arrest cell cycle at G0–G1, and induce apoptosis in both vemurafenib (VEM)-sensitive and VEM-resistant.

A, indicated model systems were cultured in media containing complete serum, harvested, and lysed; total protein was separated by SDS-PAGE, transferred.

Driver pathways and key genes in OSCC

An example of a possible specialized application of metformin in cancer treatment. An example of a possible specialized application of metformin in cancer.

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

MEK1/2-ERK1/2-p190RHOGAP and INK4a/ARF deficiency drive RHOA activation in NSCLC. A and B, G-LISA assay showing RHOA-GTP levels in H460, A549, and H838.

Therapeutic strategies for different classes of BRAF and MEK mutations

MITF-low/NF-κB–high transcriptional class is present and associated with resistance to MAPK pathway inhibition in human tumors. MITF-low/NF-κB–high transcriptional.

Bioinformatic analyses suggest that PI3K/AKT signaling may be a key downstream pathway of tazarotene signaling. Bioinformatic analyses suggest that PI3K/AKT.

Illustration of the point-counting technique applied to estimate hippocampal volume from MR images of a control (C, top row), patient with left-sided seizure.

Presentation transcript:

Top, NEPC biology is estimated to drive approximately 25% of the lethal prostate cancers indicated by the blue zone. Top, NEPC biology is estimated to drive approximately 25% of the lethal prostate cancers indicated by the blue zone. Bottom, mitotic and neural development pathways have been implicated in the progression to the androgen-independent NEPC and offer targets, such as small-molecule inhibitor of AURKA, that might change the course of the disease by inhibiting both the mitotic and neural program. Because NEPC is often found mixed with AR-positive adenocarcinoma, an understanding of adaptive AR signaling in this context is also needed. Ana Aparicio et al. Cancer Discovery 2011;1:466-468 ©2011 by American Association for Cancer Research